Amgen 2012 Annual Report Download - page 146
Download and view the complete annual report
Please find page 146 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136 -
137 -
138 -
139 -
140 -
141 -
142 -
143 -
144 -
145 -
146 -
147 -
148 -
149 -
150
 |
 |
F-47
agreement in principle and continues to expect to enter into a written settlement agreement to resolve a fourth Other Qui Tam, for
which Amgen has accrued an immaterial amount; that matter will remain under seal in the U.S. federal court where it was filed
until the settlement agreement is signed. The fifth and final Other Qui Tam action remains under seal in the U.S. federal court in
which it was filed and includes allegations that Amgen's promotional, contracting, sales and marketing activities and arrangements
relating to Aranesp®, NEUPOGEN®, Neulasta®, XGEVA®, Prolia®, Vectibix® and Nplate® caused the submission of various false
claims under the Federal Civil False Claims Act and various State False Claims Acts. Amgen continues to cooperate fully with
the government in its investigation of these allegations.
Commitments
We lease certain facilities and equipment related primarily to administrative, R&D, sales and marketing activities under non-
cancelable operating leases that expire through 2032. The following table summarizes the minimum future rental commitments
under non-cancelable operating leases as of December 31, 2012 (in millions):
2013 $ 121
2014 97
2015 90
2016 79
2017 67
Thereafter 287
Total minimum operating lease commitments $ 741
Included in the table above are future rental commitments for abandoned leases in the amount of $331 million. Rental expense
on operating leases for the years ended December 31, 2012, 2011 and 2010, was $117 million, $131 million and $115 million,
respectively.
In addition, we have minimum contractual purchase commitments with third-party manufacturers through 2014 that total
$39 million as of December 31, 2012. Amounts purchased under these contractual purchase commitments for the years ended
December 31, 2012, 2011 and 2010, were $123 million, $87 million and $68 million, respectively.